Recent findings suggest that visfatin can drive the differentiation of monocytes into M2-like tumour-associated lymphocytes by inducing CXCL1 [102], with M2-like macrophages playing a crucial role in escalating tumour malignancy rates. The gene discussed is CXCL1; the disease is neoplasm.